Signature moléculaire de l étiologie des cancers de la thyroïde. CEA / DSV / IRCM Sylvie Chevillard

Transcription

1 Signature moléculaire de l étiologie des cancers de la thyroïde CEA / DSV / IRC Sylvie Chevillard

2 Principe de l analyse 57 tumeurs de la thyroïde induites post-radiothérapie hybridations sur puces 25K 50-52mers RNG/RC collection Recherche de mutations dans les gènes BRA, Ras et remaniements RET/ 30 adénomes folliculaires TA 27 carcinomes papillaires Groupe d apprentissage 7 sporadic TA 7 RI-induced 7 sporadic 7 RI-induced Groupe de validation 16 TC 13

3 Clinical data of radiation-induced tumors - learning set Patient Histology Sex Age at IR Cause Age at tumor diagnosis (yr) Dosimetry (Gy) RA1 TA 13 Acne RA2 TA RA3 TA RA4 TA 8 Non-Hodgkin lymphoma RA5 TA 9 Nasopharynx carcinoma RA6 TA RA7 TA 5 Non-Hodgkin lymphoma ean = 7 yr ean = 38 yr edian = 8 yr edian = 36 yr RP1 6 Acute lymphoblastoid leukemia 20? RP2 11 Non-Hodgkin lymphoma RP RP4 10 Lymphoma RP5 7 Neuroblastoma RP RP ean = 10 yr ean = 32 yr edian = 10 yr edian = 30 yr

4 Clinical data of sporadic tumors - learning set Patient Histology Sex Age at tumour diagnosis (yr) SA1 A 59 SA2 A 63 SA3 A 48 SA4 A 22 SA5 A 44 SA6 A 24 SA7 A 21 ean = 40 yr edian = 44 yr ean = 38 yr edian = 36 yr SP1 54 SP2 27 SP3 25 SP4 44 SP5 39 SP6 34 SP7 23 ean = 35 yr edian = 34 yr ean = 32 yr edian = 30 yr

5 Gene expression analysis 7 sporadic A 7 sporadic Learning set 7RI A 7RI Included at least one tumour of each histology 4 tumours 4 tumours At least a 50% difference in their tumour compositions (per aetiology) After permutations, 143 combinations have been retained Sporadic tumours RI tumours ST1 ST2 ST3 ST4 RT1 RT2 RT3 RT4 atrix 1 Not considered Retained gene Retained gene Retained gene Probability density to be higher expressed ore than 95% of difference between the two calculated probabilities Probability density to be lower expressed ST2 ST4 ST6 ST7 RT2 RT4 RT6 RT7 Retained gene Genes identified as discriminating in more than 70% of the 143 RI/S combinations Retained gene atrix 2 Not considered Retained gene SIGNATURE all RI vs all S 325 genes

6 Blind validation of the RI/S signature Validation of the signature by - principal component analysis (PCA) - calculation of the quadratic distance (Root ean Square (RS)) Sporadic follicular adenomas Sporadic papillary carcinomas Radio-induced tumors Papillary carcinomas ollicular adenomas

7 Patients Well classified Radiation-induced Signature Sex Histology A Clinical data prediction Age at IR Age at tumour diagnosis (yr) Dosimetry (Gy) XA12 A R R Sporadic follicular adenomas Sporadic papillary carcinomas Radio-induced tumours

8 XA2_Well classified sporadic A Patients Sex Histology XA2 Signature prediction Clinical data A S S Age at tumour diagnosis (yr) 59 Sporadic follicular adenomas Sporadic papillary carcinomas Radio-induced tumours

9 Patients XP7_Well classified Histology sporadic Signature Sex prediction XP7 Clinical data S S Age at tumour diagnosis (yr) 22 Alteration / Sporadic follicular adenomas Sporadic papillary carcinomas Radio-induced tumours

10 Patients XP9_Undetermined Sex Histology papillary Signature carcinoma Clinical data prediction XP11? R Age at IR 23 Age at tumour diagnosis (yr) Dosimetry (Gy) Alteration 3 Sporadic follicular adenomas Sporadic papillary carcinomas Radio-induced tumours

11 Blind validation of the R/S signature Validation set 16 follicular adenomas 13 papillary carcinomas Clinical datas 8 SA 8 RA 8 SP 5 RP Signature prediction 6 SA 2 RA 8 RA 8 SP 4 RP 1? 26/29 well classified 2/29 miss-classified 1/29 undetermined etiology RI S + test (RI) test (S) 0 14 Sensitivity 12/ Specificity 14/ Positive predictive value 12/ Negative predictive value 14/14 1 Proportion of RI tumours well concluded among RI tumours Proportion of S tumour well concluded among S tumours Proportion of tumour with + test (R), well concluded Proportion of tumours with test (S), well concluded

12 Signature of radiation-induced tumours after radiotherapy olecular signature : 325 genes when considering all sporadic tumours versus all RI-induced tumours 138 over-expressed and 187 under-expressed genes RI-induced compared with sporadic tumours Less stringent analysis dysregulated pathways 656 genes 313 over-expressed genes and 343 under-expressed genes in RI tumours as compared with sporadic tumours

13 Transcriptome analysis 981 genes 170 genes already reported in thyroid microarrays 80 genes associated to normal or pathological thyroid molecular mechanisms 8 genes dysregulated in sporadic vs post-tchenobyl (Port et Al. 2007) ST150, RARRES1, GZH, C13orf3, SRP1, RIPK4, EPB41L3, RERG Comparaison difficile à cause des références qui sont différentes APK, EGR, WNT, TG Regulation of p53 and p53-dependant regulation Angiogenesis, Hypoxia

14 Signatures in each histological group Signatures were found when considering : Sporadic versus RI Sporadic A versus RI A Less robust in term of well classification than all sporadic vs all RI tumours signature

15 Nicolas Ugolin Kathy Ory Schlumberger P Hofman Adel El Nagar CE P6 ED

16 Sporadic vs Tchernobyl Tchernobyl Sporadic Learning Tchernobyl Sporadic

17 Tchernobyl signature Signature of sporadic tumours versus post-tchernobyl tumours 495 genes S R Pool R S R Ref Ref Pool S Normal Normal 12 genes in common with the 325 genes post-radiotherapy signature 19 genes in common when post-radiotherapy signature is extended (less stringency) 66 genes already reported in thyroid microarrays 4 genes deregulated in sporadic vs post-tchenobyl (Port et Al. 2007)

18 Alterations in RAS, BRA and RET genes Papillary carcinomas ollicular adenomas Patients RET/ BRA Ras Patients Ras RP1 RA1 RI Learning Validation RP2 RP3 RP4 RP5 RP6 RP7 XP9 XP10 XP11 XP12 XP13 RET/3 RET/1 RET/3 V600E Kras Q61R RI Learning Validation RA2 RA3 RA4 RA5 RA6 RA7 XA9 XA10 XA11 XA12 XA13 XA14 XA15 XA16 Hras Q61R Kras Q61K S Learning Validation SP1 SP2 SP3 SP4 SP5 SP6 SP7 XP1 XP2 XP3 XP4 XP5 XP6 XP7 XP8 RET/3 RET/1 RET/1 V600E V600E V600E V600E V600E V600E 3bp deletion V600E S Learning Validation SA1 SA2 SA3 SA4 SA5 SA6 SA7 XA1 XA2 XA3 XA4 XA5 XA6 XA7 XA8 Hras Q61R Nras Q61R Nras Q61K

19 Clinical data from radiation-induced tumours of the validation set Patient Histology Sex Age at IR Cause Age at tumour diagnosis (yr) Dosimetry (Gy) XA9 A 19? 40? XA10 XA11 XA12 XA13 XA14 XA15 A A A A A A? ? Non-Hodgkin lymphoma ? Unavailable XA16 A 28 Uterus XP XP10 13 Ovarian teratoma XP11 24 Lymphoma XP XP13 19 Graves disease 39 Unavailable

20 Clinical data from sporadic tumors of the validation set Patient Histology Sex Age at tumour diagnosis (yr) XA1 A 58 XA2 A 31 XA3 A 29 XA4 A 29 XA5 A 27 XA6 A 59 XA7 A 22 XA8 A 48 XP1 17 XP2 25 XP3 39 XP4 17 XP5 74 XP6 73 XP7 41 XP8 40

21 Radiation-induced tumors of the learning set Sporadic tumors of the learning set Age at tumour diagnosis BRA RET/ No alteration RET/, BRA Women en Sex